Skip to content
Trial Agents

Siemens Healthcare Laboratory

Siemens Healthcare Laboratory is recorded as a service provider in 4 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.

4distinct trials
3recorded service labels
1trials with learnings

Data snapshot: 2026-10-09 · About the data

Clinical trial experience

Showing 4 of 4 trials · Latest update first

An open-label, single arm, multi-center extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with relapsing multiple sclerosis (RMS)

Sponsor Novartis Pharma AG

Start (EU)
Latest update
Estimated end

An Open-Label, Rater-Blind, Randomized, Multi-Center, Parallel-Arm, Active-Comparator Study to Assess the Efficacy and Tolerability of Ofatumumab 20mg SC monthly vs. First Line DMT - physician’s choice in the treatment of newly diagnosed RMS (STHENOS)

Sponsor Novartis Pharma AG

Start (EU)
Latest update
Estimated end
Not reported
Operational learnings available3 trial-level findings · Read insights
  • The trial enrolled 185 participants at 41 centres across Germany, France, Italy, and Spain.
  • A 2022 protocol amendment enlarged the eligible population, reduced protocol complexity, and revised eligibility criteria to align with current ofatumumab and other DMT product information.
  • A 2021 protocol amendment required full routine laboratory testing at every on-site visit from baseline through Month 15.

These findings describe the trial, not the service provider’s performance or responsibility.

Questions about this trial experience

What services are recorded for Siemens Healthcare Laboratory?

The 2026-10-09 snapshot links Siemens Healthcare Laboratory to 4 distinct CTIS trials. Recorded services include NfL Analysis, Biomarker analysis (NfL), ELF. These are study-specific roles, not a complete or independently verified capability catalogue.

Which therapeutic areas and study phases are recorded for Siemens Healthcare Laboratory?

The most frequently recorded therapeutic areas are Neurology, Immunology. Recorded phases include Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.

In which countries are trials linked to Siemens Healthcare Laboratory conducted?

The linked trials record locations in 23 countries, including Germany, Spain, France, Poland, Belgium. These are trial locations, not confirmed office locations or countries where Siemens Healthcare Laboratory delivered services.

What can this page tell me about Siemens Healthcare Laboratory's trial experience?

Browse 4 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.

About this data & company names

One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.

Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.

Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Siemens Healthcare Laboratory. Legacy brands remain separate unless explicitly matched in the name registry.

View recorded company names
  • Siemens Healthcare Laboratory LLC

Never miss a new clinical trial insight

We continuously analyze new and updated clinical trial data and publish practical, evidence-led reports for clinical leaders.